State of Michigan Retirement System purchased a new position in shares of Omnicell, Inc. (NASDAQ:OMCL – Get Rating) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund purchased 11,200 shares of the company’s stock, valued at approximately $975,000.
Several other institutional investors also recently modified their holdings of OMCL. Vanguard Group Inc. boosted its holdings in shares of Omnicell by 0.3% in the first quarter. Vanguard Group Inc. now owns 4,752,906 shares of the company’s stock valued at $615,453,000 after buying an additional 12,413 shares during the period. Macquarie Group Ltd. lifted its holdings in shares of Omnicell by 12.5% in the second quarter. Macquarie Group Ltd. now owns 1,218,279 shares of the company’s stock worth $138,579,000 after acquiring an additional 135,360 shares during the last quarter. Clearbridge Investments LLC lifted its holdings in shares of Omnicell by 1.2% in the second quarter. Clearbridge Investments LLC now owns 1,150,473 shares of the company’s stock worth $130,866,000 after acquiring an additional 13,809 shares during the last quarter. Lazard Asset Management LLC lifted its holdings in shares of Omnicell by 1,045.9% in the second quarter. Lazard Asset Management LLC now owns 884,541 shares of the company’s stock worth $100,616,000 after acquiring an additional 807,348 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in Omnicell by 0.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 848,688 shares of the company’s stock valued at $109,901,000 after buying an additional 4,839 shares during the last quarter.
Insider Buying and Selling
In other Omnicell news, CEO Randall A. Lipps sold 2,500 shares of the firm’s stock in a transaction on Thursday, December 1st. The stock was sold at an average price of $50.78, for a total transaction of $126,950.00. Following the completion of the transaction, the chief executive officer now owns 88,348 shares of the company’s stock, valued at $4,486,311.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, EVP Scott Peter Seidelmann sold 1,793 shares of Omnicell stock in a transaction dated Monday, November 28th. The stock was sold at an average price of $51.46, for a total value of $92,267.78. Following the completion of the sale, the executive vice president now directly owns 38,996 shares in the company, valued at approximately $2,006,734.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Randall A. Lipps sold 2,500 shares of the business’s stock in a transaction dated Thursday, December 1st. The shares were sold at an average price of $50.78, for a total value of $126,950.00. Following the sale, the chief executive officer now owns 88,348 shares of the company’s stock, valued at $4,486,311.44. The disclosure for this sale can be found here. Insiders sold 9,674 shares of company stock valued at $476,839 over the last quarter. 2.76% of the stock is owned by company insiders.
Omnicell Stock Up 0.8 %
Omnicell (NASDAQ:OMCL – Get Rating) last issued its quarterly earnings results on Wednesday, November 2nd. The company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.66 by $0.04. Omnicell had a net margin of 3.67% and a return on equity of 9.74%. The business had revenue of $348.06 million for the quarter, compared to analysts’ expectations of $362.72 million. As a group, analysts expect that Omnicell, Inc. will post 1.62 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of research analysts recently issued reports on OMCL shares. KeyCorp dropped their price objective on shares of Omnicell from $130.00 to $75.00 and set an “overweight” rating for the company in a report on Thursday, November 3rd. Wells Fargo & Company reduced their target price on shares of Omnicell from $158.00 to $71.00 and set an “overweight” rating for the company in a research note on Friday, November 4th. JPMorgan Chase & Co. cut their price target on shares of Omnicell from $140.00 to $57.00 and set a “neutral” rating on the stock in a report on Friday, November 18th. BTIG Research cut their price target on shares of Omnicell from $160.00 to $75.00 and set a “buy” rating on the stock in a report on Thursday, November 3rd. Finally, StockNews.com downgraded shares of Omnicell from a “hold” rating to a “sell” rating in a report on Thursday. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $82.11.
Omnicell Company Profile
Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.
- Get a free copy of the StockNews.com research report on Omnicell (OMCL)
- MarketBeat: Week in Review 01/02-01/06
- Why is the CrowdStrike Stock Price Struggling?
- Four Undervalued Healthcare Stocks for 2023
- WWE Stock: Vince McMahon Wants Back In The Show
- NVIDIA Is Bottoming But Don’t Buy It Just Yet
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.